

Philippines wants money back from Sanofi for dengue vaccine

8 December 2017, by Jim Gomez



Eric John Vital, 12, holds his vaccination record as he joins other protesters at a rally outside the Department of Health to demand accountability to government officials involved in the controversial immunization of the anti-dengue vaccine Dengvaxia to more than 700,000 Filipino children Friday, Dec. 8, 2017 in Manila, Philippines. The controversial vaccine, manufactured by Sanofi Pasteur was put on hold by the Philippines last week after new study findings showed it posed risks of severe cases in people without previous infection. The controversy has prompted the Philippine Senate to conduct an investigation. (AP Photo/Bullit Marquez)

The Philippine government will demand a refund of 3.5 billion pesos (\$69.5 million) from vaccine maker Sanofi Pasteur and look at possible legal action after a study showed the vaccine used in a dengue immunization program could expose some people to severe illness, the health chief said Friday.

Health Secretary Francisco Duque III said the government will also seek compensation for treatment of children who may develop severe dengue. No deaths have been confirmed, but at least one immunized child has developed dengue.

The Department of Health put on hold its dengue immunization drive, which was launched last year and is the world's first such public program, after France-based Sanofi Pasteur released the study last week.

More than 730,000 public school children aged 9 and above in three Philippine regions with high rates of dengue fever have received at least the first dose of Dengvaxia, the first licensed dengue vaccine.

Sanofi Pasteur said its long-term follow-up study of the vaccine showed sustained benefits for up to six years for those who had a previous dengue infection, but that people who never had dengue had an increased risk of a severe case and hospitalization from the third year after immunization.

"We will demand the refund of the 3 billion paid for the Dengvaxia and that Sanofi set up an indemnification fund to cover the hospitalization and medical treatment for all children who might have severe dengue," Duque said at a news conference, adding that a government legal team will also look into Sanofi's accountability.



Protesters display placards during a rally outside the Department of Health as they demand accountability for government officials involved in the controversial immunization of the anti-dengue vaccine Dengvaxia to more than 700,000 Filipino children Friday, Dec. 8, 2017 in Manila, Philippines. The controversial vaccine, manufactured by Sanofi Pasteur, was put on hold by the Philippines last week after new study findings showed it posed risks of severe cases in people without previous infection. The controversy has prompted the Philippine Senate to conduct an investigation. (AP Photo/Bullit Marquez)

Protesters display placards during a rally outside the Department of Health as they demand accountability for government officials involved in the controversial immunization of the anti-dengue vaccine Dengvaxia to more than 700,000 Filipino children Friday, Dec. 8, 2017 in Manila, Philippines. The controversial vaccine, manufactured by Sanofi Pasteur was put on hold by the Philippines last week after new study findings showed it posed risks of severe cases in people without previous infection. The controversy has prompted the Philippine Senate to conduct an investigation. (AP Photo/Bullit Marquez)

The pharmaceutical giant initially claimed that the vaccine was safe and effective for all people aged 9 to 45, but later acknowledged that it "is not recommended for people who have had no prior dengue infection" due to the risk of a severe case, Duque said.

Duque said the Philippines will wait for a recommendation to be released next week by a group of immunization experts who provide advice to the World Health Organization.

At least one 12-year-old from northern Tarlac province developed dengue after being immunized but recovered, Duque said, although he did not say if Dengvaxia caused the infection.

WHO says about half the world's population is at risk of dengue, with a recent estimate indicating 390 million infections per year.

Another possible dengue case was being investigated, he said.

Dengue is a mosquito-borne viral infection found in tropical and subtropical climates worldwide. It is a flu-like disease that can cause joint pain, nausea, vomiting and a rash and can cause breathing problems, hemorrhaging and organ failure in severe cases.

Sanofi Pasteur said Friday it's working with Philippine authorities to address fears and share new information about the vaccine, and will cooperate in an ongoing review of the public vaccination program.

© 2017 The Associated Press. All rights reserved.



APA citation: Philippines wants money back from Sanofi for dengue vaccine (2017, December 8) retrieved 15 October 2019 from <https://medicalxpress.com/news/2017-12-philippines-money-sanofi-dengue-vaccine.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.